Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a new drug, RO4929097, can work with cetuximab,
a drug already approved for colorectal cancer, to help fight the patient's cancer. Cancers
arise as a result of abnormal control of gene expression. One of the pathways that gets
abnormally regulated in some cancers is the Notch pathway. RO4929097 is an investigational
drug that blocks the activation of the Notch pathway. It is hoped that by blocking this
abnormal activation, this drug may be helpful in patients with cancer but the investigators
do not yet know if that is true. Cetuximab is an antibody against epidermal growth factor
receptor and is known to have activity in metastatic colorectal cancer. Recent studies have
shown that people with colorectal cancers that contain a mutation in a gene called K-ras do
not benefit from receiving cetuximab. It is unknown if adding RO4929097 to cetuximab would
benefit patients who have tumors with this mutation.